- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Millbrae Today
By the People, for the People
Eikon Therapeutics Prices Upsized IPO at $18 Per Share
The biopharmaceutical company expects to raise around $381 million in its Nasdaq debut.
Feb. 4, 2026 at 9:47pm
Got story updates? Submit your updates here. ›
Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced the pricing of its upsized initial public offering of 21,177,600 shares of common stock at $18 per share. The company expects to raise approximately $381 million in gross proceeds from the IPO, which is set to begin trading on the Nasdaq Global Select Market on February 5, 2026 under the ticker symbol 'EIKN'.
Why it matters
Eikon's IPO represents a significant milestone for the company as it seeks to develop innovative medicines to address serious unmet medical needs, particularly in the field of oncology. The additional capital raised will help fund the company's pipeline of drug candidates and further its mission of integrating traditional biology research with advanced engineering to deliver better treatments faster.
The details
The IPO consists of 21,177,600 shares of common stock, with an additional 30-day option for the underwriters to purchase up to 3,176,640 more shares. J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho are acting as joint book-running managers for the offering. Eikon's common stock is expected to begin trading on the Nasdaq Global Select Market on February 5, 2026.
- Eikon Therapeutics priced its IPO on February 4, 2026.
- Eikon's common stock is expected to begin trading on the Nasdaq Global Select Market on February 5, 2026.
- The offering is expected to close on or about February 6, 2026.
The players
Eikon Therapeutics, Inc.
A late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address serious unmet medical needs, with a focus on oncology.
J.P. Morgan
One of the joint book-running managers for Eikon's IPO.
Morgan Stanley
One of the joint book-running managers for Eikon's IPO.
BofA Securities
One of the joint book-running managers for Eikon's IPO.
Cantor
One of the joint book-running managers for Eikon's IPO.
Mizuho
One of the joint book-running managers for Eikon's IPO.
What’s next
The offering is expected to close on or about February 6, 2026, subject to the satisfaction of customary closing conditions.
The takeaway
Eikon Therapeutics' successful IPO demonstrates the strong investor appetite for innovative biopharmaceutical companies with promising drug pipelines, particularly in the oncology space. The additional capital will enable Eikon to further advance its mission of developing better medicines faster through the integration of traditional biology research and advanced engineering.
